Kazia Therapeutics (ASX:KZA) clinical trial update presentation, FNN Investor Event, October 2018, Sydney

Company Presentations

Kazia Therapeutics Limited (ASX:KZA) CEO and Executive Director Dr James Garner provides an update on the company's two clinical stage drug development candidates for the treatment of brain and ovarian cancer at FNN's Investor Event.

Key points:

- Cancer drug developer for clinical trails in ovarian cancer and brain cancer
- Planned collaborations for other forms of cancer
- Strong team with experience in big pharma and early-stage biotech
- Glioblastoma (GBM) - most common and aggressive form of brain cancer
- New treatment options needed for brain cancer
- NASDAQ & ASX listed

For more, watch CEO and Executive Director Dr James Garner present. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.